Title: Federica Sotgia: Innovator in Cancer Treatment
Introduction
Federica Sotgia is a prominent inventor based in Ottawa, Canada. She is currently associated with Lunella Biotech, Inc. Federica has made significant contributions to the field of cancer research, focusing on innovative therapeutic agents.
Latest Patent Applications
Federica's notable patent application is titled "ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS." This application discusses alkyl-triphenylphosphonium compounds that possess a saturated, linear alkyl chain of about 9 to about 18 carbons. These compounds are proposed as therapeutic agents for cancer treatment. The demonstrative compound dodecyl-TPP (d-TPP) has been shown to dose-dependently inhibit the propagation of breast cancer stem cells. It targets the adherent 'bulk' of cancer cells by decreasing MCF-7 cell viability. Furthermore, d-TPP potently inhibits mitochondrial oxygen consumption rate while shifting cell metabolism toward the glycolytic pathway. This metabolic shift may help eradicate the residual glycolytic cancer stem cell population by using additional metabolic stressors. For instance, d-TPP can be combined with a glycolytic inhibitor or an OXPHOS inhibitor to treat cancer effectively.
Conclusion
Federica Sotgia is an innovative inventor dedicated to advancing cancer treatment through her research and patent applications. Her work holds promise for developing new therapeutic strategies against cancer.